References
  1. Chan, K. H., Farouji, I., Slim, J., Shaaban, H. S., & Guron, G. Tranexamic acid: A potential treatment option for coronavirus disease 2019. Journal of Global Infectious Diseases, 2020, 12(3), 160.‏
  2. ASAKURA, Hidesaku; OGAWA, Haruhiko. Potential of heparin and nafamostat combination therapy for COVID‐19. Journal of Thrombosis and Haemostasis, 2020, 18.6: 1521-1522.‏
  3. BARKER, Andrew B.; WAGENER, Brant M. An Ounce of Prevention May Prevent Hospitalization. Physiological Reviews, 2020, 100.3: 1347-1348.‏
  4. PARTHVI, Rukma; MEHRA, Sunil. Risk of pulmonary embolism due to tranexamic acid: a case study. American journal of therapeutics, 2018, 25.4: e512-e514.‏
  5. IJAOPO, Ezekiel Oluwasayo; IJAOPO, Ruth Oluwasolape; ADJEI, Sampson. Bilateral pulmonary embolism while receiving tranexamic acid: a case report. Journal of medical case reports, 2020, 14.1: 1-6.‏
  6. OGAWA, Haruhiko; ASAKURA, Hidesaku. Consideration of tranexamic acid administration to COVID-19 patients. Physiological reviews, 2020, 100.4: 1595-1596.‏
  7. HELMS, J., Clere-Jehl, R., Bianchini, E., Le Borgne, P., Burban, M., Zobairi, F, et al. Thrombomodulin favors leukocyte microvesicle fibrinolytic activity, reduces NETosis and prevents septic shock-induced coagulopathy in rats. Annals of intensive care, 2017, 7.1: 1-10.‏
  8. COCCHERI, Sergio. COVID-19: The crucial role of blood coagulation and fibrinolysis. Internal and emergency medicine, 2020, 15.8: 1369-1373.‏
  9. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Hemost, 2020;18(4):844–7.
  10. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 2020:1421–4.
  11. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-segment elevation in patients with Covid-19 - a case series. N Eng J Med 2020.
  12. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet 2020;395(10234):1417–8.
  13. BESTER, Janette; PRETORIUS, Etheresia. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Scientific reports, 2016, 6.1: 1-10.‏
  14. Tucker T, Idell S. Plasminogen‐plasmin system in the pathogenesis and treatment of lung and pleural injury. Semin Thromb Hemost. 2013; 39: 373‐ 381.
  15. Wu Y, Wang T, Guo C, et al. Plasminogen improves lung lesions and hypoxemia in patients with COVID‐19. QJM. 2020;113(8):539‐545.
  16. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID‐19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858.